Butyrophilins Role in Colon Cancer
Launched by INSTITUT PAOLI-CALMETTES · Dec 2, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the role of specific molecules called BTNL in colon cancer. The researchers want to understand if measuring these molecules can help predict how well a patient might do after treatment. The trial is currently looking for participants who are at least 18 years old and have a type of colon cancer that can be surgically removed. This includes patients whose cancer has spread to the liver but can still be treated with surgery.
To be eligible, participants should be in good overall health, meaning they can carry out daily activities without too much difficulty. Unfortunately, people with certain conditions, like rectal cancer, previous colon cancer recurrences, or certain digestive diseases, cannot take part in this trial. If you join, you'll likely have regular check-ups and tests to see how the treatment is working and to monitor the BTNL levels. This study could provide valuable information that may help doctors in the future with colon cancer treatment decisions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient is older than 18 years old,
- • Signed participation consent,
- • Non-metastatic colon cancer immediately resectable or metastatic and liver synchronous for which it was decided a combined colic and liver surgery (metastatic patient at the outset) in multidisciplinary consultation meeting.
- • Performance Status (PS) 0 or 1
- • affiliated to the social security or beneficiary
- Exclusion Criteria:
- • Rectal cancer, colon cancer recurrence
- • Emergency of colon cancer Surgery
- • History of inflammatory disease of the digestive tract (Crohn's disease or ulcerative colitis)
- • Patient who received neoadjuvant therapy other than chemotherapy
- • Patient treated with immune-suppressors or long-course corticosteroids \<12 months
- • Pregnant women or likely to be pregnant (without effective contraception) or breastfeeding,
- • Person in urgent situation, person under legal protection measure, or unable to express his / her consent,
- • Impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons
About Institut Paoli Calmettes
Institut Paoli-Calmettes (IPC) is a leading cancer research and treatment center located in Marseille, France, dedicated to advancing oncology through innovative clinical trials and comprehensive patient care. With a multidisciplinary approach, IPC integrates cutting-edge research, education, and clinical services to enhance cancer prevention, diagnosis, and treatment. The institute is committed to fostering collaboration among researchers, healthcare professionals, and patients, aiming to translate scientific discoveries into effective therapeutic strategies. As a recognized institution in the field of oncology, IPC plays a pivotal role in shaping the future of cancer care and improving patient outcomes through rigorous and ethical clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Marseille, , France
Marseille, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials